Why do people worry that TRT causes prostate cancer?
The idea that testosterone fuels prostate cancer traces back to a 1941 paper by Charles Huggins, who demonstrated that surgical castration (which dramatically lowers testosterone) caused regression in men with advanced prostate cancer — work for which he later received the Nobel Prize. The logical inference drawn for decades was: if low testosterone shrinks prostate cancer, high testosterone must accelerate it.
That inference made intuitive sense and became embedded in clinical training for much of the 20th century. Testosterone was considered contraindicated in men with any prostate concern, and TRT was avoided broadly as a result.
The problem is that the inference was never supported by prospective data — and subsequent research has substantially complicated the picture.
The saturation model: the key conceptual shift
The saturation model, developed by Abraham Morgentaler and colleagues and published in the Journal of Urology, reframes the testosterone-prostate relationship. The core hypothesis: androgen receptors in prostate tissue become fully saturated at relatively low testosterone concentrations — roughly 200–250 ng/dL total testosterone.
Once receptors are saturated, additional testosterone does not further stimulate prostate tissue. Think of it like a sponge: once fully saturated with water, adding more water does not make it "more wet" — it simply runs off. Prostate tissue at saturation does not respond to additional androgen stimulus.
This explains two observations that the old model could not reconcile:
- Why castration (dropping testosterone to near-zero, far below saturation) causes tumor regression — it removes the androgen drive completely.
- Why restoring testosterone from hypogonadal levels (below saturation) to normal physiological levels (above saturation) does not appear to accelerate prostate cancer — tissue was already at or beyond saturation in the normal range.
The saturation model does not mean testosterone is harmless in all contexts. But it provides a biologically coherent explanation for why TRT at physiological doses does not appear to carry the prostate cancer risk the older model predicted.
Once prostate androgen receptors are saturated, adding more testosterone is like pouring water on an already-soaked sponge — it simply runs off.
What contemporary research shows
Large observational studies comparing men on TRT to matched non-TRT controls have consistently failed to find increased prostate cancer incidence in the TRT group. The concern has not borne out epidemiologically.
The most important recent data comes from the TRAVERSE trial — a large, randomized, placebo-controlled trial of testosterone replacement in hypogonadal men with elevated cardiovascular risk, published in the New England Journal of Medicine in 2023. TRAVERSE was powered to evaluate cardiovascular safety, but also collected prostate data as a secondary endpoint.
TRAVERSE found that testosterone therapy did not increase the overall incidence of prostate cancer over the trial period. PSA levels rose slightly more in the testosterone group than placebo, as expected (testosterone stimulates PSA production even without driving cancer), but prostate cancer diagnosis rates were not statistically different between arms.
The Endocrine Society’s 2018 guidelines explicitly state that “we have no evidence that testosterone therapy causes prostate cancer” and do not list TRT as a risk factor for prostate cancer development in men with normal PSA and no prior prostate cancer history.
Who should not start TRT due to prostate concerns?
Despite the updated evidence, several groups remain contraindicated or require special caution:
- Active or untreated prostate cancer: This remains a firm contraindication. TRT is not prescribed to men with known active prostate cancer. The saturation model applies to normal prostate tissue; it does not guarantee safety in the setting of established malignancy.
- Elevated or rising PSA without workup: A PSA above 3–4 ng/mL at baseline, or a PSA that has been rising rapidly, warrants urological evaluation before TRT is initiated. Prostate cancer workup should precede testosterone initiation in these cases.
- Palpable prostate nodule: A suspicious finding on digital rectal examination warrants urology evaluation before TRT.
- Treated prostate cancer — nuanced: Men who have completed treatment for localized prostate cancer and achieved durable PSA remission are an evolving category. Some specialist clinicians now offer TRT to carefully selected, long-remission men after risk-benefit discussion. This is not standard care and requires specialist involvement. Metastatic prostate cancer remains a contraindication.
PSA monitoring during TRT
Although TRT does not appear to cause prostate cancer, responsible TRT management includes PSA surveillance as a standard component of ongoing care. Testosterone stimulates PSA secretion from prostate cells, so PSA will typically rise modestly in the first months of TRT even in men without prostate pathology.
The Endocrine Society recommends checking PSA at 3–12 months after TRT initiation, then annually in men over 40. The following PSA thresholds warrant urology referral:
- PSA increase of more than 1.4 ng/mL within any 12-month period
- PSA velocity above 0.4 ng/mL per year over 2 or more years
- Any confirmed PSA above 4.0 ng/mL (or above 3.0 ng/mL in high-risk groups, such as African American men or men with first-degree relatives with prostate cancer)
This monitoring structure does not reflect a belief that TRT causes prostate cancer — it reflects the reality that prostate cancer is common in older men, TRT raises PSA, and surveillance catches cancers that would have developed regardless of TRT. The monitoring protects men by ensuring new cancers are detected promptly.
How clinician-supervised TRT handles prostate safety
A clinician-supervised TRT program addresses prostate safety as a first-class concern throughout the process:
- Pre-treatment PSA: Baseline PSA is drawn before any testosterone is prescribed. Elevated or borderline values trigger additional workup or referral before initiation.
- Ongoing PSA surveillance: Follow-up PSA at 3–12 months and annually thereafter flags changes that warrant further evaluation.
- Dose management: TRT is dosed to physiological range, not supraphysiological levels. The saturation model arguments apply to physiological replacement — supraphysiological dosing carries a different risk profile and is outside the standard of care for hypogonadism treatment.
- Urology coordination: For men with borderline PSA or prior prostate history, TRT is managed in coordination with urology, not independently.
FAQs: TRT and prostate cancer
Does TRT cause prostate cancer?
Current evidence does not support a causal link between testosterone replacement therapy at physiological doses and the development of prostate cancer. Large observational studies and randomized trials have not found that TRT increases prostate cancer incidence in men with normal baseline PSA. The Endocrine Society and major urology guidelines do not list TRT as a cause of prostate cancer.
Can men with a history of prostate cancer use TRT?
Men with active or untreated prostate cancer are contraindicated for TRT. Men who have been treated for localized prostate cancer and achieved undetectable PSA for a sustained period are increasingly being considered on an individualized basis by some clinicians, but this remains an evolving area and requires specialist involvement. TRT is not appropriate for men with metastatic prostate cancer.
What PSA level is too high to start TRT?
Clinical guidelines do not specify a single absolute PSA cutoff, but most clinicians are cautious about initiating TRT with a PSA above 3–4 ng/mL without further urology evaluation, or in the presence of a palpable prostate nodule. Elevated baseline PSA warrants prostate cancer workup before TRT is initiated.
How often should PSA be checked on TRT?
The Endocrine Society recommends checking PSA at 3–12 months after TRT initiation, then annually in men over 40. A PSA rise of more than 1.4 ng/mL above baseline within 12 months, or any confirmed PSA above 4 ng/mL, warrants urology referral.
What is the prostate saturation model?
The saturation model proposes that prostate androgen receptors are fully saturated at relatively low testosterone levels (roughly 200–250 ng/dL). Above that threshold, additional testosterone does not further stimulate prostate tissue. This explains why castrate-level testosterone in prostate cancer treatment causes tumor regression, but TRT in hypogonadal men does not appear to accelerate cancer risk — testosterone is already near or at saturation in those with normal prostate tissue.